Krill Oil and Muscle in Older Adults

• Sponsor: University of Glasgow (Other)
• Overall Status: Completed
• CT.gov ID: NCT04048096
• Collaborator: (none)
• Enrollment: 102
• Location: 1
• Arms: 2
• Actual Duration (Months): 24.1
• Patients Per Site Per Month: 4.2

Study Details

Study Description

Brief Summary

The aim of this study is to determine the effects of krill oil supplementation on muscle mass in function in older adults. Half of the participants will receive krill oil supplements and the other half a placebo.

Condition or Disease	Intervention/Treatment	Phase
Aging; Sarcopenia	Dietary Supplement: Krill Oil; Dietary Supplement: Placebo	N/A

Study Design

• Study Type: Interventional
• Actual Enrollment: 102 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Effects of Krill Oil Supplementation on Muscle Function in Older Adults
• Actual Study Start Date: Mar 7, 2018
• Actual Primary Completion Date: Mar 10, 2020
• Actual Study Completion Date: Mar 10, 2020

Arms and Interventions

Arm	Intervention/Treatment
Placebo Comparator: Placebo 4g/day of mixed vegetable oil supplements	Dietary Supplement: Placebo; Mixed vegetable oil
Experimental: Krill 4g/day krill oil	Dietary Supplement: Krill Oil; Aker Biomarine Superba Krill Oil

Outcome Measures

Primary Outcome Measures

1. Change in Muscle strength [Change from baseline to 6 months]

   knee extensor muscle strength

Secondary Outcome Measures

1. Change in Grip strength [Change from baseline to 6 months]

   Grip strength

2. Change in Muscle thickness [Change from baseline to 6 months]

   Vastus lateralis muscle thickness

3. Change in Short performance physical battery test [Change from baseline to 6 months]

   SPPB

4. Change in Body Fat [Change from baseline to 6 months]

   Measured by BIA

5. Change in Lean Mass [Change from baseline to 6 months]

   Measured by BIA

6. Change in Fasting glucose [Change from baseline to 6 months]

   Fasting glucose

7. Change in Blood lipids [Change from baseline to 6 months]

   Blood lipids

8. Change in CRP [Change from baseline to 6 months]

   CRP

9. Change in Erythrocyte fatty acid profile [Change from baseline to 6 months]

   Erythrocyte fatty acid profile

Eligibility Criteria

Criteria

• Ages Eligible for Study: 65 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• BMI less than 35kg/m2

Exclusion Criteria:

• Diabetes

• severe cardiovascular disease

• seizure disorders

• uncontrolled hypertension (>150/90mmHg at baseline measurement)

• cancer or cancer that has been in remission <5 years

• ambulatory impairments which would limit ability to perform assessments of muscle function

• dementia

• taking medication known to affect muscle (e.g. steroids)

• have an implanted electronic device (e.g. pacemaker/defibrillator/insulin pump)

• on anticoagulant therapy

• allergies to seafood

• regular consumption of more than 2 portions of oily fish per week.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Stuart Robert Gray	Glasgow		United Kingdom

Sponsors and Collaborators

• University of Glasgow

Investigators

• Principal Investigator: Stuart Gray, PhD, University of Glasgow

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Stuart Gray, Senior Lecturer in Exercise and Metabolic Health, University of Glasgow
• ClinicalTrials.gov Identifier: NCT04048096
• Other Study ID Numbers: 200170067
• First Posted: Aug 7, 2019
• Last Update Posted: Nov 3, 2020
• Last Verified: Nov 1, 2020

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Sarcopenia

Study Results

No Results Posted as of Nov 3, 2020